Drug-resistant hypertension is defined as suboptimal blood pressure control despite the treatment with at least three blood pressure-lowering drugs. Up until now, choosing a 4th add-on drug in these patients has been a doctor’s subjective preference more than a scientifically sound decision. Well, these times are over because Bryan Williams and colleagues found out what you should do in these patients in the so-called PATHWAY-2 trial, which was published in the Lancet in September 2015. Watch the above video to learn all about it.
What’s the next step?
If you want to become an expert on all things relating to diuretics, then check out our Fluids and Electrolytes Masterclass where we will teach you everything you need to know about this hot topic.
PS: Make sure to download the summary infographic below!
Previous videos reviews
- #6: The modified Valsalva maneuver - Video Review
- #5: Optimal Duration of Dual Antiplatelet Therapy
- #4: Dual Versus Triple Therapy In Patients Undergoing Stent Implantation Who Are On Anticoagulation
- #3: Three in One: Atrial Fibrillation Incidence, Safety of Transcatheter Valves & Duration of Triple Therapy After Stent Implantation
- #2: Oral Contraceptives and Risk of Venous Thromboembolism
- #1: Air versus Oxygen in St-Segment-Elevation Myocardial Infraction
If you want to receive more teaching videos, make sure to like us on facebook